Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Rasha W Al-Ali(Institute of Cancer Research), Christopher S. Hourigan(National Heart Lung and Blood Institute), Steven M. Devine(National Marrow Donor Program), Kristin Page(Medical College of Wisconsin), Antonio Jiménez(University of Miami), Zoë C. Wong(National Institutes of Health), Coleman Lindsley, Marcos de Lima(The Ohio State University), Devdeep Mukherjee(National Institutes of Health), Karina Elias(MesoScribe Technologies (United States)), Firas El Chaer(The University of Texas MD Anderson Cancer Center), Jeffrey E. Miller(MesoScribe Technologies (United States)), Austin Jacobsen(MesoScribe Technologies (United States)), Georgia Andrew(National Institutes of Health), Scott L. Zeger(Johns Hopkins University), Laura W. Dillon(Institute of Cancer Research), Wael Saber(Medical College of Wisconsin), Stephen R. Spellman(National Marrow Donor Program), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Mark R. Litzow(Mayo Clinic in Arizona), Jeffery J. Auletta(Nationwide Children's Hospital), Jerald P. Radich(University of Washington), Ying Huang(MesoScribe Technologies (United States)), Matt Holman(MesoScribe Technologies (United States)), Jason Gerhold(MesoScribe Technologies (United States)), J. D'Angelo(MesoScribe Technologies (United States)), Gege Gui(Johns Hopkins University), Niveditha Ravindra(National Institutes of Health)
Transplantation and Cellular Therapy
February 1, 2025
Cited by 0


Related Papers